Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinbryta in relapsing-remitting multiple sclerosis (SELECTION)
NCT00870740Phase 2Completed
- Sponsor
- Biogen
- Start
- Feb 2009
- Primary completion
- May 2012
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS) (6 arms), sponsored by Biogen. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at 72 weeks, Number of Participants With Abnormalities in Vital Signs at 72 weeks and 3 more. Started Feb 2009; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00870740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00870740.